Pre-market
Loading markets…
Stocks

What's Going On With Navion Capital II Inc. Stock Wednesday?

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:NVN-P.V

Follow NVN-P

Photos provided by Pexels

Navion Capital II Inc. remains steady in the market as it navigates recent developments.

This week, Navion Capital II Inc. (NVN-P.V) has experienced no change in its stock price, closing at C$0.06. The company continues to make headlines with its proposed qualifying transaction and ongoing developments in the healthcare sector.

Navion Capital II Inc.

NVN-P.V

Full stock page →

NVN-P.V

Navion Capital II Inc.

Source:WealthAwesomeWealthAwesome
↑ $0.00 (0.00%)
120 day period
$0.06$0.56$0.06Dec 31Apr 9Oct 2

Market cap

$253,000

52W high

$0.06

52W low

$0.06

1W change

+0.00%

Beta

0.57

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on NVN-P's historical volatility

HistoricalForecast68%95%
C$0.05C$0.05C$0.05C$0.06C$0.06C$0.06TodayFeb 23Apr 30Oct 2Nov 14Dec 28Feb 9

30-Day Vol

0.0%

Annualized

90-Day Vol

0.0%

Annualized

Trend (90d)

+0.0%

Annualized drift

90d Mean

C$0.06

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$0.06C$0.06 – C$0.06
60 trading daysC$0.06C$0.06 – C$0.06
90 trading daysC$0.06C$0.06 – C$0.06

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Investor takeaway: Investors should monitor the upcoming transaction with Maple Brain Healthcare Inc. while considering the company's financial position and market activity.

Market Cap: C$253,000

Despite a modest market cap, Navion Capital II's strategic moves may attract attention in the evolving healthcare landscape.

Bull case

The proposed transaction with Maple Brain Healthcare Inc. could position Navion Capital II for growth in the expanding AI healthcare market. This partnership may enhance its business prospects and open up new opportunities in a rapidly developing sector.

Bear case

Navion Capital II's lack of profitability and a high negative return on equity could raise concerns among investors, especially given the competitive market landscape. These factors may lead to skepticism regarding the company's long-term viability.

Recent Price Action

Navion Capital II Inc. closed at C$0.06 this week, maintaining a steady position with no changes in its stock price over the past week. The performance remains consistent with a year-to-date change of 0.00%, indicating a stable trading environment.

Company News and Developments

Navion Capital II recently made headlines with its proposed qualifying transaction with Maple Brain Healthcare Inc., an AI software and medical device company. This non-binding letter of intent was announced on October 27, 2025, and may offer the company new growth opportunities in the healthcare sector. Additionally, there was a trading halt by the Canadian Investment Regulatory Organization on the same date due to pending news, highlighting the significance of this potential transaction.

Technical Picture

From a technical standpoint, Navion Capital II is currently trading at its 50-day and 200-day moving averages, both at C$0.06, indicating a lack of volatility and a stable price level. The stock has a beta of 0.65, suggesting lower volatility compared to the broader market. Its trading volume is consistent with the average, reflecting steady investor interest.

Financial Overview

Navion Capital II's financial metrics reveal a P/E ratio of 5.5, which may indicate undervaluation relative to its earnings potential. However, the company has a profit margin of 0.0% and a negative return on equity of -63.8%, raising concerns about its profitability and operational efficiency. As of now, the company's market cap stands at C$253,000.

Price Action Summary

As of the latest close, Navion Capital II Inc. remains at C$0.06, with no percentage change over the last day. Investors are encouraged to keep an eye on future developments, particularly regarding the proposed transaction with Maple Brain Healthcare Inc.

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: September 16, 2026
Last Updated: October 12, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26